Domainex, a drug research services company, has appointed Dr Trevor Perrior as CEO, effective from 1 October 2018.
Dr Perrior has held the position of Director of Research and Chief Scientific Officer at Domainex since 2005. The company has grown significantly during his tenure, delivering numerous development candidates across several therapeutic areas.
Following his education at the University of Cambridge, Dr Perrior undertook academic research at Cambridge, Oxford and in the US. He then held senior R&D roles in pharmaceutical and biotechnology companies ICI, Zeneca, AstraZeneca and Celltech, where he worked on sites in the UK, US and Switzerland.
Dr Perrior is also a scientific consultant to a number of venture capital and charitable organisations and is the Visiting Professor of Medicinal Chemistry at The University of Sussex.
“I am delighted to formalise Trevor’s leadership position in the company," said Dr Timo Veromaa, executive chairman.
“The executive team was recently strengthened by Chris Brown joining as CFO and with Tom Mander as COO continuing to lead business development, I am confident the company is well positioned as a high quality service provider. With Trevor now taking the helm I will step down and Tony Brampton will resume duties as non-executive chairman.”
“I am honoured to be offered this exciting opportunity to lead Domainex into a new growth period,” commented Dr Perrior.
“I believe we are in a strong position to build on our expanding scientific capabilities to serve our global client base. I look forward to working with the whole Domainex team to devise and implement our future growth strategies in drug research services. We aim to further increase our business in mainland Europe and in the US where we have just opened two sales offices.”
